Articles tagged with Drug Studies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A small clinical trial showed 40% of patients experienced progression-free survival when treated with a CD105 inhibitor, which prevented cancer cells from making splice variant proteins. This approach may resensitize select patients to androgen suppression therapy.
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A new study found that only 12% of middle-aged adults are willing to participate in dementia prevention drug trials, citing concerns over the risks involved. The study suggests prioritizing those with a family history or perceived personal risk for dementia and communicating about trial safety could increase participation.
The Alpha Stem Cell Clinic will develop preclinical studies into early and later phase clinical trials with the goal of establishing advanced regenerative medicine treatments. The clinic will also foster greater collaboration with eight similar clinics across the state and educate the public about stem cell and related therapies.
Dr. Volpp's research on behavioral economics and health incentives has significantly advanced understanding of cardiovascular outcomes, leading to changes in benefit design and program offerings. He is also the founder of Penn Center for Health Incentives and Behavioral Economics.
A comparison of two cancer drugs reveals that life cycle management strategy is crucial for a drug's commercial success. The research found that product sales are closely linked to the number of approved indications and inter-organizational alliances.
A new daily anti-clotting pill, edoxaban, shows promise in preventing bleeding and clotting instances rare in children with heart conditions. The study's findings indicate edoxaban is a viable alternative to current treatments, eliminating injections and reducing frequent blood tests.
Researchers at Weill Cornell Medicine have developed a new computational method to map the architecture of human tissues in unprecedented detail. This approach enables powerful new diagnostic strategies for a wide range of diseases, including cancer and chronic conditions.
A large-scale comparison of direct oral anticoagulants has identified apixaban as the drug with the lowest risk of bleeding. The study, published in Annals of Internal Medicine, found that apixaban had a 19-28% lower risk of gastrointestinal bleeding compared to other DOACs.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
The TRIDENT-1 trial suggests that repotrectinib could be effective for treating ROS1 positive non-small cell lung cancer (NSCLC) in patients who have received other targeted treatments and those who have not. The drug showed promising results, with an objective response rate of 79% in patients not previously treated with a ROS TKI.
Researchers have successfully isolated parathyroid stem cells and maintained them in lab as organoids for an extended period. These patient-derived parathyroid organoids (PTOs) closely mimic human parathyroid tissue, enabling the study of parathyroid diseases and drug development.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A study found that nearly half of Medicaid beneficiaries who completed opioid rehab did not receive follow-up care or medication-assisted treatment within a month. Patients with prior prescriptions for opioid use disorder medications were 24% more likely to get follow-up care and medication.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
In a patient trial, the AKT inhibitor ipatasertib showed signs of effectiveness in treating advanced cancers. 22% of patients experienced tumor shrinkage, while 56% had stable disease. Further research is needed to understand why some patients responded and others did not.
A phase I clinical trial found that Omomyc (OMO-103) has few side effects and can stabilize disease in some patients. The treatment showed stabilization of disease in 8 out of 17 evaluable patients, including one patient with pancreatic cancer who remained on the study for over six months.
Dr. Christine E. Seidman, a renowned physician-scientist, has made groundbreaking discoveries in genetics and cardiomyopathy, leading to new pharmacological treatments. Her work has improved our understanding of disease risks and has led to unique targeted therapies.
The NCI-MATCH precision medicine cancer trial found a promising signal for the AKT inhibitor ipatasertib, meeting its primary endpoint with a 22% response rate in patients with rare AKT1 E17K tumor gene mutations. The study demonstrated clinically significant activity in patients, warranting additional studies.
RedHill Biopharma's Talicia demonstrates high potential for H. pylori eradication while minimizing systemic antibiotic exposure, outperforming generic rifabutin regimens. Movantik data shows improved patient quality of life and symptom improvement in opioid-induced constipation.
A new drug combination of cefepime and enmetazobactam has been found to be more effective in treating complicated urinary tract infections and acute pyelonephritis than a standard treatment. The study showed that the new combination was successful in treating 79% of patients, compared to 58.9% for the conventional treatment.
Studies on 18beta-glycyrrhetinic acid, human islet amyloid polypeptide (hIAPP), and fluoroquinolone derivatives explore new approaches to treating challenging diseases. Researchers aim to develop better therapeutics for liver diseases, which cause almost 2 million deaths worldwide every year.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A new study by Université Laval researchers has identified a link between insulin receptors in brain microvessels and Alzheimer's disease. The findings suggest that drugs targeting these receptors could be effective in treating the condition, expanding the range of potential treatments.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
The study will gather data from over 500 adults with monkeypox to determine the effectiveness and safety of tecovirimat. Participants with severe disease or high risk of severe disease will receive open-label tecovirimat, while others will be randomly assigned to receive either tecovirimat or placebo.
A meta-analysis of six studies concludes that electroconvulsive therapy (ECT) is more effective than ketamine in quickly relieving major depression symptoms. The analysis, published in JAMA Psychiatry, found no significant differences in ECT's success rate across various age groups and geographic locations.
Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.
Scientists are conducting a first-of-its-kind study to investigate the origin of psychedelic compounds in fungi, including psilocybin found in 'magic mushrooms'. The research aims to understand the evolution of these compounds and their potential applications in medicine and conservation.
A study found that 16.5% of American adults with diabetes ration their insulin, with younger adults and the uninsured being most affected. Insulin rationing is often linked to cost concerns, with many patients delaying purchases or taking less insulin than needed.
Research reveals that pregnant smokers decrease their daily cigarette count by an average of one cigarette per day before realizing they are pregnant. This trend continues in the month following pregnancy recognition, with a decline from nine to five cigarettes per day on average.
A pilot study will investigate the use of medicinal cannabis to ease symptoms in children and adolescents with non-oncological conditions. The trial aims to determine acceptability and feasibility, with potential breakthroughs for treating debilitating symptoms such as pain and seizures.
A clinical trial begins in the Democratic Republic of Congo to evaluate tecovirimat's safety and effectiveness in treating monkeypox. The trial will enroll up to 450 participants, comparing those who receive tecovirimat to placebo, and gather data on disease severity, mortality, and recovery.
A long-term study found that older patients with type 2 diabetes treated with glitazones had a 22% lower risk of developing dementia. These drugs may effectively prevent dementia in high-risk patients and are now worth prioritizing for future clinical studies.
A large clinical trial found that insulin glargine and liraglutide were superior to other diabetes drugs in controlling blood sugars. The study, published in the New England Journal of Medicine, compared four common medications used to treat type 2 diabetes when added to metformin.
Researchers at NYU Grossman School of Medicine have discovered a new treatment approach that suppresses allergic asthma without compromising the body's defenses against flu viruses. The treatment, which targets calcium channels in immune cells, has shown promise in reducing asthmatic inflammation and mucus build-up in mice.
Researchers at CNIC have identified metoprolol as a neuroprotective agent after a stroke, greatly reducing cerebral inflammation and neuronal death. The study's findings suggest that metoprolol may also offer benefits in treating severe Covid-19.
A Phase I/II study found tofacitinib effective in improving skin and organ issues in systemic sclerosis patients. The drug was well-tolerated, with minimal impact on T-cells, suggesting potential repurposing for treatment.
A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.
Researchers at the University of Pittsburgh discovered that a cellular channel outside the kidneys plays a crucial role in maintaining healthy blood pressure levels. The study found that subtle mutations in this channel can influence blood pressure, providing a potential new target for existing medications.
A clinical trial of email alerts from pharmacists to doctors and other practitioners found no reduction in risky opioid prescribing, highlighting the need for rigorous testing of policies aimed at making opioid prescribing safer. The study tested behavioral science techniques to encourage safer prescribing practices.
A Johns Hopkins Medicine study found that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults. The results support the CDC vaccination guidelines recommending COVID-19 boosters and highlight the importance of continued research on factors affecting immunity.
A team of researchers identified a protein kinase substrate downstream of the dopamine signaling pathway regulating brain reward behavior. The study found that phosphorylation of potassium voltage-gated channel subfamily Q member 2 (KCNQ2) decreases its channel activity, increasing neuronal excitability and promoting reward behavior.
Scientists have designed compounds that activate the 5HT2a receptor, producing antidepressant and antianxiety effects in mice. The compounds' mechanism of action differs from psychedelics like LSD, offering a potential new approach to developing effective antidepressants with fewer side effects.
Researchers from Xi'an Jiaotong-Liverpool University found that brain stimulation combined with a nose spray containing nanoparticles can improve recovery after ischemic stroke. The treatment increased cognitive and motor functions, and weighed more quickly than those treated with TMS alone.
A recent study found that over 11,000 people treated in US emergency departments for drug-related bike injuries were men, with methamphetamine being the most common substance involved. The study highlights the need for further research and interventions to prevent these incidents.
Researchers at National Jewish Health found pirfenidone effective in slowing ILD progression in RA patients, potentially increasing overall survival. The study was the first prospective treatment trial for this condition.
Research institutes from Finland, Germany, Norway, Spain, and Sweden have launched the Federated European Genome-phenome Archive (Federated EGA) to improve data sharing across national borders. The new platform enables secure access to sensitive human data for research while respecting national data protection regulations.
Lenabasum has been shown to improve skin symptoms in patients with amyopathic dermatomyositis, demonstrating significant reductions in inflammation and disease severity. The study's findings suggest that lenabasum is a well-tolerated treatment option for refractory skin disease.
Patients undergoing virtual reality immersion during hand surgery required significantly less anesthetic to manage pain, suggesting its potential as a non-pharmacologic distraction method. The study compared VR immersion to monitored anesthesia care and found no significant differences in post-operative pain or anxiety levels.
A pioneering behavioural diagnostic tool, SPUR, has been developed to improve medication adherence in type 2 diabetes patients. The study found that the tool can reliably identify patients struggling with their medicines and the reasons why.
A new paper published in Social Science & Medicine proposes that synthetic steroids were administered to female captives in Nazi concentration camps to prevent menstruation and fertility. The study, led by Dr. Peggy J. Kleinplatz, is based on historical evidence and testimony from Holocaust survivors, who reported suspicious food ratio...
A new study suggests that spironolactone, a medication for heart problems and high blood pressure, may also be effective in reducing alcohol drinking. The research found that increasing doses of spironolactone decreased alcohol consumption in mice and rats, as well as in humans with excessive alcohol drinking.
A new study has found that a medication typically used to treat heart problems and high blood pressure may also reduce alcohol consumption in humans. The study's findings support further research into spironolactone as a potential treatment for alcohol use disorder, which affects millions of people in the US.
A new biologic drug has been found to be highly effective in reducing the signs and symptoms of moderate-to-severe eczema in infants and young children. The study showed that more than half of treated children experienced a 75% reduction in eczema symptoms, leading to improved sleep and increased ability to lead normal lives.
Tirzepatide, a new type 2 diabetes drug, has been shown to achieve blood glucose targets 4-12 weeks sooner than existing treatments. Additionally, tirzepatide was found to promote weight loss goals faster than semaglutide, with an average time of 8-24 weeks to reach target weight loss.
A new study led by Ohio State University researchers found that atezolizumab is a safe and effective treatment option for stage IB-IIIB non-small cell lung cancer patients prior to surgery, with survival rates reaching 80% at three years post-treatment. The study also identified new blood markers that can help predict treatment response.
A review article suggests that retinol-binding protein-4 (RBP4) may be a potential target for clinical intervention in non-alcoholic fatty liver disease. The study highlights the importance of RBP4 in the pathogenesis of NAFLD, including its role in inducing hepatic de novo lipogenesis and impairing fatty acid oxidation.
Researchers discovered that blocking the ion channel TRPC6 prolongs survival and improves muscle function in mice with severe Duchenne muscular dystrophy. The study also reduced bone deformities associated with weak muscles.
In a Phase I/II trial, selpercatinib demonstrated a 44% objective response rate across multiple tumor types, including pancreatic and colorectal cancers. The study found responses regardless of cancer type or prior treatment history, confirming RET fusions as a tissue-agnostic target.